May 2017 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2015/16 Invitation to Tender, dated 6 November 2015 and the 2016/17 Invitation to Tender, dated 3 November 2016.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (http://www.pgnz.org.nz/pharmacode) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors(external link)). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) |
Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Brimonidine tartrate* | Eye drops 0.2%; 5 ml OP bottle |
$4.32 | $4.29 | Arrow-Brimonidine (Actavis) |
1 December 2017 | 1 March 2018 |
| Neostigmine metisulfate | Inj 2.5 mg per ml, 1 ml; 50 ampoules |
$98.00 | $98.00 | AstraZeneca (AstraZeneca) |
1 September 2017 | 1 December 2017 |
| Rifaximin | Tab 550 mg; 56 tablets; blister pack |
$625.00 | $625.00 | Xifaxan (Norgine) |
1 July 2017 | 1 October 2017 |
| *This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2016/17 Invitation To Tender. | ||||||
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Anastrozole* | Tab 1 mg; 30 tablets; blister pack |
$26.55 | $5.04 | Rolin (Rex Medical) |
1 November 2017 | 1 January 2018 | 1 April 2018 | Aremed (AFT) Arimidex (AstraZeneca) DP-Anastrozole (Douglas) |
| Bisoprolol fumarate** | Tab 2.5 mg; 90 tablets; blister pack |
$2.40 per 30 tablets | $3.53 | Bosvate (Douglas) |
1 July 2017 | 1 September 2017 | 1 December 2017 | Bosvate (Douglas) 30 tablet pack |
| Bisoprolol fumarate** | Tab 5 mg; 90 tablets; blister pack |
$3.50 per 30 tablets | $5.15 | Bosvate (Douglas) |
1 July 2017 | 1 September 2017 | 1 December 2017 | Bosvate (Douglas) 30 tablet pack |
| Bisoprolol fumarate** | Tab 10 mg; 90 tablets; blister pack |
$6.40 per 30 tablets | $9.40 | Bosvate (Douglas) |
1 July 2017 | 1 September 2017 | 1 December 2017 | Bosvate(Douglas) 30 tablet pack |
| Ethinyloestradiol with levonorgestrel | Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablets; blister pack |
$2.65 | $2.18 | Microgynon 20 ED (Bayer) |
1 November 2017 | 1 January 2018 | 1 April 2018 | Ava 20 ED (Actavis) |
| Ethinyloestradiol with levonorgestrel | Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablets; blister pack |
$2.30 | $1.77 | Levlen ED (Bayer) |
1 November 2017 | 1 January 2018 | 1 April 2018 | Ava 30 ED (Actavis) |
| Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride | Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg; 30 sachets |
$7.65 | $6.78 | Molaxole (Mylan) |
1 December 2017 | 1 February 2018 | 1 May 2018 | Lax-Sachets (AFT) |
|
* Brand switch fee of $4.50 is payable for this product from 1 April 2018 until 1 July 2018. **The three months dispensed all-at-once (Stat dispensing) rule will be added to bisoprolol fumarate tablets from 1 December 2017. |
||||||||
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current price | New price | Hospital Supply Brand (Supplier) | DVLimit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Brimonidine tartrate* | Eye drops 0.2%; 5 ml bottle |
$4.32 | $4.29 | Arrow-Brimonidine (Actavis) |
1% | 1 December 2017 | 1 February 2018 |
| Neostigmine metisulfate | Inj 2.5 mg per ml, 1 ml; 50 ampoules |
$98.00 | $98.00 | AstraZeneca (AstraZeneca) |
1% | 1 September 2017 | 1 November 2017 |
| Rifaximin | Tab 550 mg; 56 tablets; blister pack |
$625.00 | $625.00 | Xifaxan (Norgine) |
1% | 1 July 2017 | 1 September 2017 |
| Ropivacaine hydrochloride | Inj 2 mg per ml, 10 ml ampoule; 5 ampoules |
$9.05 | $8.80 | Ropivacaine Kabi (Fresenius Kabi) |
1% | 1 July 2017 | 1 September 2017 |
| Ropivacaine hydrochloride | Inj 2 mg per ml, 20 ml ampoule; 5 ampoules |
$9.50 | $9.20 | Ropivacaine Kabi (Fresenius Kabi) |
1% | 1 July 2017 | 1 September 2017 |
| Ropivacaine hydrochloride | Inj 7.5 mg per ml, 10 ml ampoule; 5 ampoules |
$10.20 | $9.90 | Ropivacaine Kabi (Fresenius Kabi) |
1% | 1 July 2017 | 1 September 2017 |
| Ropivacaine hydrochloride | Inj 7.5 mg per ml, 20 ml ampoule; 5 ampoules |
$12.50 | $12.15 | Ropivacaine Kabi (Fresenius Kabi) |
1% | 1 July 2017 | 1 September 2017 |
| Ropivacaine hydrochloride | Inj 10 mg per ml, 10 ml ampoule; 5 ampoules | $10.90 | $10.55 | Ropivacaine Kabi(Fresenius Kabi) | 1% | 1 July 2017 | 1 September 2017 |
| Ropivacaine hydrochloride` | Inj 10 mg per ml, 20 ml ampoule; 5 ampoules | $16.30 | $15.80 | Ropivacaine Kabi(Fresenius Kabi) | 1% | 1 July 2017 | 1 September 2017 |
| Suxamethonium chloride | Inj 50 mg per ml, 2 ml ampoule; 50 ampoules | $78.00 | $78.00 | AstraZeneca (AstraZeneca) |
1% | 1 September 2017 | 1 November 2017 |
| Zinc and castor oil | Oint BP; 20 g tube | $1.39 | $1.26 | healthE (Jaychem) |
1% | 1 September 2017 | 1 November 2017 |
| *This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedules 6, clause 3.1 (b)(II) of the 2016/17 Invitation To Tender. | |||||||
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current price | New price | Hospital Supply Brand (Supplier) | DVLimit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
| Anastrozole | Tab 1 mg; 30 tablets; blister pack |
$26.55 | $5.04 | Rolin (Rex Medical) |
1% | 1 November 2017 | 1 January 2018 | Aremed (AFT) DP-Anastrozole (Douglas) |
| Bisoprolol fumarate | Tab 2.5 mg; 90 tablets; blister pack |
$2.40 per 30 tablets | $3.53 | Bosvate (Douglas) |
1% | 1 July 2017 | 1 September 2017 | Bosvate (Douglas) 30 tablet pack |
| Bisoprolol fumarate | Tab 5 mg; 90 tablets; blister pack |
$3.50 per 30 tablets | $5.15 | Bosvate (Douglas) |
1% | 1 July 2017 | 1 September 2017 | Bosvate (Douglas) 30 tablet pack |
| Bisoprolol fumarate | Tab 10 mg; 90 tablets; blister pack |
$6.40 per 30 tablets | $9.40 | Bosvate (Douglas) |
1% | 1 July 2017 | 1 September 2017 | Bosvate (Douglas) 30 tablet pack |
| Ceftazidime | Inj 1 g vial; 1 vial |
$1.55 | $2.20 | Hospira Ceftazidime (Pfizer) |
1% | 1 January 2018 | 1 March 2018 | Fortum (GSK) |
| Cefuroxime | Inj 750 mg vial; 10 vials |
$3.70 per 5 vials | $9.85 | Cefuroxime Actavis (Actavis) |
1% | 1 December 2017 | 1 February 2018 | Zinacef (GSK) |
| Cefuroxime | Inj 1.5 g vial; 10 vials |
$1.30 per vial | $14.36 | Cefuroxime Actavis (Actavis) |
1% | 1 December 2017 | 1 February 2018 | Zinacef (GSK) |
| Ethinyloestradiol with levonorgestrel | Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablets; blister pack |
$2.65 | $2.18 | Microgynon 20 ED (Bayer) |
1% | 1 November 2017 | 1 January 2018 | Ava 20 ED (Actavis) |
| Ethinyloestradiol with levonorgestrel | Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablets; blister pack |
$2.30 | $1.77 | Levlen ED (Bayer) |
1% | 1 November 2017 | 1 January 2018 | Ava 30 ED (Actavis) |
| Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride | Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg; 28 sachets |
$7.65 | $6.78 | Molaxole (Mylan) |
1% | 1 December 2017 | 1 February 2018 | Lax-Sachets (AFT) |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2016/17 Invitation to Tender, dated 3 November 2016:
2015/16 Invitation to Tender
| Chemical Name | Line Item |
|---|---|
| Condom lubricating jelly | <200 ml |
| Condoms | Female condom |
| Dorzolamide | Eye drops 2% |
2016/17 Invitation to Tender
| Chemical Name | Line Item |
|---|---|
| Calcium carbonate | Tab eff 0.875 - 1.75 g (0.5 g - 1 g elemental) |
| Cefuroxime | Oral suspension 25 mg per ml |
| Cefuroxime | Oral suspension 50 mg per ml |
| Cidofovir | Inj 75 mg per ml, 5 ml |
| Ciprofloxacin with Hydrocortisone | Ear drops 0.2% with hydrocortisone 1% |
| Coal tar | Shampoo 4% (pack size of 100 ml or less) |
| Cyclopentolate hydrochloride | Eye drops 1% |
| Fosfomycin | Powder for oral solution, 3 g sachet |
| Hydrocortisone Butyrate | Oint 0.1% (pack size of 100 g or less) |
| Ivermectin | Cream 1% |
| Lithium carbonate | Cap 250 mg |
| Lopinavir with Ritonavir | Oral liq 80 mg with ritonavir 20 mg per ml |
| Lopinavir with ritonavir | Tab 100 mg with ritonavir 25 mg |
| Mefloquine hydrochloride | Tab 250 mg |
| Methadone hydrochloride | Inj 10 mg per ml, 1 ml |
| Methotrexate | Inj 100 mg per ml, 10 ml |
| Orphenadrine Citrate | Tab 100 mg |
| Paclitaxel | Inj 150 mg |
| Paclitaxel | Inj 600 mg |
| Pivmecillinam | Tab 200 mg |
| Prednisolone acetate | Eye drops 0.12% |
| Pyrimethamine | Tab 25 mg |
| Streptomycin sulphate | Inj 400 mg per ml, 2.5 ml |
| Testosterone | Transdermal patch 5 mg |
| Testosterone | Transdermal patch 2.5 mg |
| Tobramycin | Eye drops 0.3% |
| Tobramycin | Eye oint 0.3% |
| Trimethoprim | Tab 100 mg |
| Trimethoprim | Oral liq |
| Trimethoprim with sulphamethoxazole [Co-trimoxazole] | Tab trimethoprim 80 mg and sulphamethoxazole 400 mg |
| Trimethoprim with sulphamethoxazole [Co-trimoxazole] | Tab trimethoprim 160 mg and sulphamethoxazole 800 mg |
| Verapamil hydrochloride | Tab long-acting 120 mg |
| Verapamil hydrochloride | Tab 40 mg |
| Verapamil hydrochloride | Tab 80 mg |
| Verapamil hydrochloride | Tab long-acting 240 mg |
For products included in the 2014/15, 2015/16 and 2016/17 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.